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Abstract
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thienopyridines and aspirin.
Although effective, these drugs carry risks of increased bleeding and drug ‘resistance’, underpinning a drive for new
antiplatelet agents. To discover such drugs, one strategy is to identify a suitable druggable target and then find small
molecules that modulate it. A good and unexploited target is the platelet collagen receptor, GPVI, which promotes
thrombus formation. To identify inhibitors of GPVI that are safe and bioavailable, we docked a FDA-approved drug library
into the GPVI collagen-binding site in silico. We now report that losartan and cinanserin inhibit GPVI-mediated platelet
activation in a selective, competitive and dose-dependent manner. This mechanism of action likely underpins the
cardioprotective effects of losartan that could not be ascribed to its antihypertensive effects. We have, therefore, identified
small molecule inhibitors of GPVI-mediated platelet activation, and also demonstrated the utility of structure-based
repurposing.
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Introduction
Cardiovascular disease (CVD) is a leading cause of mortality
worldwide accounting for ,1 in 3 deaths in industrialised societies
[1,2]. A number of antiplatelet therapies are currently approved
for the management of pathological thrombosis, including
cyclooxygenase (COX) inhibitors (e.g. aspirin), phosphodiesterase
(PDE) inhibitors (e.g. cilostazol), irreversible ADP receptor
antagonists (e.g. clopidogrel, prasugrel) and fibrinogen receptor
blocking antibodies (e.g. abciximab, eptifibatide). Current anti-
platelet drugs, by means of their methods of action, have
undesirable side effects including haemorrhage (gastrointestinal
and cerebral), neutropenia, headache, skin irritation and hyper-
tension. The development of new antiplatelet agents, especially
drug-like small molecules, is long overdue [3–5].
Drug repurposing is a low-risk, high-gain strategy for drug
discovery and development in which drugs used for one indication
are repurposed to treat another [6,7]. This approach reduces the
duration, cost and associated risks inherent in traditional drug
discovery. Drug repurposing is well and truly in the spotlight and is
a major focus for the pharmaceutical industry, the U.S. National
Institutes of Health and the UK’s Medical Research Council [8,9].
The application of computational approaches to drug discovery
(e.g. virtual screening, in silico docking) greatly increases the power
of lead identification and the elucidation of novel chemical
scaffolds [10–12]. Yet despite the power and promise of in silico
repurposing, such an approach has not so far been reported for
antiplatelet agents.
A sensible place to identify new targets for the development of
novel therapies is in the physiological processes that underlie the
disease. Our most successful antiplatelet agents to date (aspirin and
clopidogrel) work by directly inhibiting enzymes and receptors that
mediate the secondary phase of platelet activation. However, as
previously mentioned, undesirable side effects (inappropriate
bleeding) is a major problem with current antiplatelet agents;
new targets could yield better drugs with improved efficacy and
reduced side effects.
There is evidence to suggest that inhibition of adhesion
receptors such as the collagen receptor, GPVI, or the von
Willebrand receptor, GPIb-IX-V, may be a viable approach for
reducing pathological thrombus formation in vivo [13,14]. Platelets
adhere to exposed collagen fibres following injury of the vessel wall
(physiological response) or rupture of an atherosclerotic plaque
(pathological response). Circulating von Willibrand factor (vWF)
complexes with exposed collagen fibres and together these proteins
act as ligands for the platelet adhesion/activation receptors a2b1,
the GPIb-IX-V complex, and glycoprotein (GP) VI [15,16].
Adhesion via a2b1 and the GPIb-IX-V mediates platelet rolling
and tethering, allowing the major platelet collagen receptor,
GPVI, to interact with its ligand to mediate platelet activation.
Once engaged, GPVI initiates tyrosine kinase-dependent signal-
ling via the associated FcRc chain, which contains an immunor-
eceptor tyrosine-based activation motif (ITAM). Ca2+ release and
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subsequent granule secretion leads to the release of secondary
mediators of platelet activation, including 5-HT and ADP, that act
in an autocrine fashion. Concurrent with these events is the
generation of thrombin and fibrinogen, which leads to the
formation of a fibrin clot.
There are many mediators of platelet activation that could be
targeted for drug development. GPVI activation is an early event
in collagen-induced thrombus formation and is receiving increas-
ing attention as a potential target for antiplatelet development.
Recent characterisation of GPVI-Fc fusion proteins that block
platelet-collagen interactions [17,18], as well as the development
of humanised murine GPVI scFvs [19], have highlighted GPVI as
a therapeutic target. GPVI-Fc fusion proteins inhibit collagen
responses in animal models, demonstrating a lack of toxicity in
human trials, and no bleeding phenotype. The effectiveness of
these biologicals in reducing thrombosis is reminiscent of
endogenous mechanisms that regulate GPVI-collagen interactions
through receptor shedding at high shear [20]. These data
strengthen the argument for targeting the collagen-GPVI interac-
tion for therapeutic intervention. However, administration of
scFvs, antibodies or fusion proteins relies on intravenous injection
and is therefore not a viable approach for self-administration or
long-term use outside the clinic, especially for a highly prevalent
disease. Development of orally bioavailable small, drug-like,
GPVI-specific antagonists could, therefore, be of great therapeutic
value [13,14] as they would provide an alternative option for the
management of thrombotic risk. In this study we describe the
identification and characterisation of two selective GPVI receptor
antagonists in vitro.
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Figure 1. In silico identifies GPVI antagonists. Representative image capture of in silico docking into GPVI using Glide, with space filling model is
shown in a, and H-bonding to relevant side chains is detailed in b. The 20 highest ranking compounds were screened for effects on Ca2+ release by
the GPVI-specific agonist CRP-XL (10 mg/ml) (c and d, % refers to percent inhibition of Ca2+ release). Maximum Ca2+ release is shown in white,
compounds that inhibited Ca2+ release by ,50% or more are in grey, and the remainder in black. Commercially available compounds that inhibited
CRP-XL-induced Ca2+ release .50% were further screened by light transmission aggregometry to identify compounds displaying dose-dependent
inhibition (e-j). Examples are shown of weak antagonism (g and h) and false positives (i and j). Cinanserin (l) and losartan (k) were taken on for further
study.
doi:10.1371/journal.pone.0101209.g001
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Figure 2. Losartan and cinanserin inhibit GPVI-mediated cell activation.Washed human platelets were loaded with fura2-AM and screened
for drug-mediated inhibition of Ca2+ release by 1 mg/ml CRP-XL (n = 3, 6 SEM, representative traces and summary, a–c) and 1 mg/ml collagen (n = 3,
SEM, representative traces and summary, d–f); losartan (&) and cinanserin (m). To measure aggregation, washed human platelets were incubated
Losartan Inhibits GPVI Signalling
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Materials and Methods
Materials
4G10 anti-phosphotyrosine monoclonal antibody was pur-
chased from Millipore (Upstate, U.K.). Losartan, cinanserin and
U46619 were purchased from Tocris Bioscience (Bristol, U.K.).
All other reagents were purchased from Sigma (Poole, U.K.). The
NIH Clinical Collection (1 and 2) was purchased from Evotec (CA,
U.S.) Inc.
In silico docking
The crystal structure of human platelet glycoprotein VI (PDB
ID 2gi7) [21] was used for in silico docking. The receptor was
processed by addition of protons and flipping of Gln, His and Asn
using MolProbity [22]. The receptor was further processed using
the program FRED receptor 2.2.5 [23] and a requirement for H-
bonding of Lys 41 with the compounds was set. The docking was
performed using Fred 2.2.5 and a database of 727 compounds
with conformers pre-generated using Omega 2.2.3 [24]. The
molecules were docked and scored with FRED’s default consensus
scoring and the top 40 molecules were tested for their biological
efficacy using a CRP-XL-induced Ca2+ release assay.
Isolation of human platelets
Whole blood was taken from healthy volunteers (following
written consent) and collected into 50 ml syringes containing 5 ml
4% sodium citrate in accordance with procedures approved by the
Local Research Ethics Committee (Milton Keynes Ref: 07/
Q1603/17). Platelet-rich plasma (PRP) was isolated by centrifu-
gation at 2006g for 10 minutes at room temperature. PRP was
pooled and 10 mg PGI2 was added before centrifugation at
10006g for 10 minutes at room temperature. Platelets were
resuspended in 1ml Tyrodes buffer (134 mM NaCl, 0.34 mM
Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 5 mM
glucose, 1 mM MgCl2, pH 7.3) pre-warmed to 30uC and 150 ml
ACD. The volume was adjusted to 25 ml with Tyrodes buffer,
followed by addition of 3 ml ACD and 1.25 mg PGI2. Cells were
centrifuged at 10006g for 10 minutes at room temperature and
the resultant cell pellet was resuspended in pre-warmed Tyrodes
buffer to a final cell density of 46108 cells/ml (aggregations) or
26109 cells/ml (peptide pull downs). Where appropriate, 1 mM
ethylene glycol tetraacetic acid (EGTA), 10 mM indomethacin and
2 U/ml apyrase were added to inhibit platelet aggregation
(referred to as non-aggregating conditions).
Light transmission aggregometry
Platelets (450 ml) were stimulated with agonist in a final volume
of 500 ml at 37uC with continuous stirring (1200 rpm) in an optical
aggregometer. For drug studies, platelets were incubated with
losartan or cinanserin for 60 s after which time, agonist was added
and aggregations monitored using AGRO/LINK8 software
(Chrono-log Corp., Pennsylvania, U.S.A).
In vitro assessment of Ca2+ release
Washed human platelets were incubated with 3 mM fura-2 AM
for 1 hour at 30uC before being washed once in Tyrodes buffer
and resuspended at 46108 cells/ml. Changes in fluorescence were
measured in a BMG Fluostar Optima plate reader using excitation
wavelengths of 340 nm and 380 nm. [Ca2+]i was calculated using
the following formula: [Ca2+]i = Kd6 (Rmin)/(Rmax –R)6Sfb,
where Kd (for Ca
2+ binding to fura-2 at 37uC) = 225 nM,
R=340/380 ratio, Rmax = 340/380 ratio under Ca2+-saturating
conditions, Rmin = 340/380 ratio under Ca2+-free conditions,
and Sfb = ratio of baseline fluorescence (380 nm) under Ca2+-free
and -bound conditions [25]. For drug studies, compounds were
pre-incubated with the platelets for 2 minutes at 37uC with orbital
shaking before the addition of agonist.
Western blotting
Samples were boiled in Laemmli buffer (working concentration
50 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol (DTT), 2%
sodium dodecyl sulfate (SDS), 0.01% bromophenol blue, 10%
glycerol). Proteins were resolved on NuPAGE pre-cast Tris-
Glycine gels (Invitrogen, U.K.) prior to transfer onto nitrocellulose
at 70 mA per gel for 40–60 min. Membranes were blocked in 5%
non-fat milk powder/Tris-buffered saline/0.1% Tween-20
(TBST; 50 mM Tris, 150 mM NaCl, 0.1% Tween-20) with
gentle agitation for one hour at room temperature (RT) or
overnight at 4uC. Primary antibody was added to the membranes
at the appropriate dilution in 5% Marvel/TBST with gentle
agitation for 1.5 h at RT or overnight at 4uC. Membranes were
washed 3 times in 16 TBST for 10 minutes. The appropriate
HRP-conjugated secondary antibody (DAKO) was added to the
membranes in 5% non-fat milk powder/TBST and incubated at
room temperature for 45 min with gentle agitation. Membranes
were washed 3 times in 16 TBST for 10 min. Bands were then
visualised with ECL Plus detection reagent (GE Lifesciences, Little
Chalfont, U.K.) using an AGFA Curix developer.
Flow cytometry
P-selectin and FITC-fibrinogen binding. Whole blood
(5 ml) was incubated with 2 ml anti-CD62P-phycoerythrocynin
with drug for one minute prior to the addition of 1 mg/ml CRP-XL (representative traces and summary shown in g–i) or 1 mg/ml collagen
(representative traces and summary shown in j–l).
doi:10.1371/journal.pone.0101209.g002
Table 1. IC50 values for losartan and cinanserin on both CRP-XL- and collagen-induced Ca
2+ release and aggregation.
Ca2+ RELEASE AGGREGATION
CRP COLLAGEN CRP COLLAGEN
losartan 4 2 4 4
cinanserin 40 40 35 40
Washed human platelets were assessed for effects on Ca2+ release and aggregation (n = 3–5). Values are in mM.
doi:10.1371/journal.pone.0101209.t001
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(PE) conjugates antibody (BD Bioscience, UK) and 2 ml fluorescein
isothiocyanate (FITC)-fibrinogen (DAKO, Ely, U.K.), drugs and
agonist, in a final volume of 50 ml Tyrodes-HEPES buffer. To this,
a CRP-XL was added to a final concentration of 1 mg/ml and
incubated at room temperature for 10 minutes. Samples were then
fixed in 2 ml 0.2% formyl saline (sterile filtered). Exposure of P-
selectin (CD62P) and FITC-fibrinogen binding was measure using
a BD Accuri C6 flow cytometer. GPVI levels: Whole blood (5 ml)
was incubated with drug for 10 minutes at room temperature. To
this, 2 ml anti-GPVI antibody (GPVI (HY101, M.L. Kahn,
University of Pennsylvannia, 1 mg/ml) was added and incubated
for 10 mins at room temperature. Donkey anti-mouse antibody
conjugated to Alexa Fluor 647 was added to the samples and
incubated at room temperature for a further 10 minutes. Samples
were then fixed in 2 ml 0.2% formyl saline (sterile filtered) and
read on a BD Accuri C6 flow cytometer.
Results
In silico docking yields high hit rate and streamlines
screening
A library of 727 FDA-approved drugs and their diastereomers
were docked into the GPVI ligand binding site, with an emphasis
on the electrostatic environment at the Lys41 position (Figure 1a
and 1b). Lys41 lies within the floor of the groove that forms the
collagen binding site of GPVI [21,26,27] and compounds were
ranked on their ability to bind in this region. Using a single point
screen (Ca2+ release) with a high dose of drug (100 mM) and a high
dose of cross-linked collagen related peptide (CRP-XL, 10 mg/ml),
we found that docking yielded a high success rate; of the top 20
compounds, 14 inhibited CRP-XL-induced Ca2+ release from
fura2-AM-loaded washed human platelets by $50% (Figure 1c
and 1d). Then, using light transmission aggregometry over a
limited (5–6 point) 3-fold dilution series from 100 mM to 300 nM,
we re-screened those drugs that had demonstrated inhibition of
Ca2+ release and were commercially available, to identify those
which gave concentration-dependent inhibition of GPVI-mediated
aggregation (Figure 1e-k). Of these drugs, some were false positives
(e.g. altanserin and pirenpirone – Figure 1i and j) while others
showed only weak antagonism (e.g. zaleplon and deoxyadenosine
– Figure 1g and h). Cinanserin and losartan both demonstrated
concentration-dependent inhibition with suitable IC50 values
(Figure 1e and f) and were therefore selected for further
investigation.
Cinanserin (Figure 1l) was the highest ranking hit (#1) from the
docking and preliminary experiments indicated that it had an IC50
in the micromolar range. The angiotensin II type I receptor
antagonist losartan (Figure 1m) also ranked highly as a potential
antagonist (#10). Retrospective literature searches revealed that
this compound had previously been reported to interact with the
collagen binding pocket of GPVI [28] and inhibit platelet
aggregation both in vitro [29] and in vivo [30]. The fact that
losartan has been shown to interact with GPVI at the collagen
binding site in an independent study validates our methodology
and provides confidence that our docking parameters are
appropriate. Losartan was included in subsequent experiments
as it serves not only as a positive control, but also as a potential
drug for repurposing if found to be selective and efficacious;
losartan is a well-tolerated drug. Cinanserin was also included for
further characterisation as it was ranked with the greatest
probability of interacting with GPVI, and exhibited robust
inhibition of Ca2+ release (Fig. 1c and 1e). The high success rate
of our computational screen (14 out of 20 compounds inhibited
CRP-XL-induced Ca2+ release in vitro) validates the use of an in
silico docking strategy for identifying potential receptor antagonists.
Figure 3. Losartan and cinanserin demonstrate selectivity for
GPVI. Ca2+ release and aggregations were carried out with 5 mM of the
P2Y12 receptor agonist 2-MeSADP (a, Ca
2+ release and b, aggregation),
or 0.5 U/ml of the PAR1 and PAR4 receptor agonist thrombin (c, Ca2+
release and d, aggregation). Losartan (X); cinanserin (m), n = 3, 6 SEM.
For global tyrosine phosphorylation, washed human platelets were
incubated with drug or vehicle alone before addition of 1 mg/ml CRP-XL
or collagen. Samples were collected at 10, 30, 60 or 90 seconds (as
indicated by the graduated bars with time increasing to the right) in ice
cold 26 lysis buffer and separated on 4–12% NuPage gels under
reducing conditions. Tyrosine phosphorylation was visualized with
4G10 anti-phosphotyrosine antibody. Losartan and cinanserin reduce
CRP-XL- (e) and collagen-(f) induced global tyrosine phosphorylation,
but have no effect on thrombin or 2-MeSADP induced global tyrosine
phosphorylation (g). Both drugs reduce FcRc phosphorylation (h),
(unphosphorylated, lower band; phosphorylated, upper band).
doi:10.1371/journal.pone.0101209.g003
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Losartan and cinanserin inhibit Ca2+ release and
aggregation in washed human platelets
We next conducted more detailed studies to determine precise
IC50 values for losartan and cinanserin using platelet functional
assays. Ca2+ release induced by the GPVI-specific agonist CRP-
XL, and the endogenous ligand collagen, was measured and
quantified. Both drugs inhibited Ca2+ release in a concentration-
dependent manner in response to both CRP-XL (Figure 2a–c) and
collagen (Figure 2d–f). Cinanserin and losartan had IC50 values in
the micromolar range, with losartan having an IC50 value of
4 mM, 10-fold greater than that of cinanserin (40 mM). To
determine whether the inhibitory effect of losartan and cinanserin
on Ca2+ release could be translated into effects on gross platelet
function, we carried out light transmission aggregometry using
washed human platelets. Both drugs exhibit dose-dependent
inhibition of platelet aggregation in response to both CRP-XL
(1 mg/ml, Figure 2g–i) and collagen (1 mg/ml, Figure 2j–l). IC50
values were comparable to those for Ca2+ release and are
summarised in Table 1.
Losartan and cinanserin are selective inhibitors
Losartan and cinanserin inhibit CRP-XL- and collagen-induced
Ca2+ release and aggregation. To experimentally determine the
selectivity of these compounds we tested their ability to antagonise
other platelet agonists. Ca2+ release and aggregation responses to
the P2Y12 receptor agonist 2-MeSADP (5 mM), and the PAR1/4
agonist thrombin (0.5 U/ml), in the presence and absence of drug,
were measured. Losartan and cinanserin had minimal effects on
P2Y12–mediated platelet activation, although some high concen-
tration effects (at 100 mM) were observed for MeSADP-induced
Ca2+ release (Figure 3a) and aggregation (Figure 3b). With regards
to thrombin, little or no effect is seen for both Ca2+ release
(Figure 3c) or aggregation (Figure 3d).
Engagement of GPVI with its ligand induces tyrosine
phosphorylation of the associated FcRc chain on conserved
tyrosine residues within its ITAMs [31] by Src family kinases that
are non-covalently associated with the receptor. This phosphor-
ylation leads to recruitment and activation of the tyrosine kinase
Syk, which mediates phosphorylation of a number of downstream
targets leading to an increase in global tyrosine phosphorylation
[32]. Both losartan and cinanserin reduced global tyrosine
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phosphorylation induced by the GPVI-specific agonist CRP-XL
(Figure 3e), and the endogenous ligand collagen (3f). No effect on
either thrombin- or 2-MeSADP-induced global tyrosine phos-
phorylation (90 s) was observed (Figure 3g). In addition, incuba-
tion of drug (30 mM) prior to the addition of CRP-XL reduced
phosphorylation of the FcRc chain (Figure 3h), indicating that
losartan and cinanserin prevent phosphorylation of the ITAM and
initiation of phosphotyrosine signalling following ligand engage-
ment.
Recent studies pertaining to the antiplatelet effects of losartan
have focused mainly on its inhibition of thromboxane A2 receptor
(TPR) signaling [33,34], rather than collagen. When platelet rich
plasma is isolated from mice that have been injected with losartan
(10 mg/kg) for 5 days, aggregation responses to the TPR agonist,
U46619, are inhibited, and these inhibitory effects extend to
thrombus formation in vivo [30] (FeCl3-induced injury model). Yet
our studies indicate that losartan is, thus far, relatively selective for
GPVI. To address this discrepancy, we examined the effects of
losartan and cinanserin on U46619 (1 mM)-induced platelet
aggregation in washed human platelets. Losartan (Figure 4a) has
an IC50 of ,20 mM for U46619-induced platelet aggregation,
compared to ,2–4 mM for collagen (1 mg/ml) and CRP-XL
(1 mg/ml) (Table 1). These results indicate that while losartan
inhibits some component of TP receptor signalling, its effects on
the GPVI receptor are more potent. Cinanserin had no effect on
U46619-mediated aggregation (Figure 4b).
To determine the relative contribution of TPR signalling to the
inhibitory effects of losartan, we measured P-selectin (CD62P)
exposure and FITC-fibrinogen binding in whole human blood in
the presence or absence of the TPR-specific antagonist, SQ-29548
(50 nM). Cinanserin was included as a control as this drug has no
effect on U46619-induced platelet activation (Figure 4b). Losartan
significantly reduced FITC-fibrinogen binding, and P-selectin
exposure, beyond that of SQ-29548 alone (Figure 4c). Adding
both compounds together results in a level of inhibition similar to
that of losartan alone. Cinanserin also significantly reduced FITC-
fibrinogen binding and P-selectin exposure when compared to
SQ-29548 alone (Figure 4d). This data shows that the inhibitory
effects of losartan on GPVI-mediated platelet activation are not
due solely to effects on TPR. There is an additional inhibitory
effect on CRP-XL-induced platelet activation above and beyond
its effects on TPR that similar to that of cinanserin.
GPVI antagonists compete for ligand binding
From the data presented above, losartan and cinanserin
demonstrate selectivity for inhibition of GPVI-mediated platelet
activation. For a small molecule pharmacological agent, a
competitive mechanism of action is preferable [35], so we set
out to determine whether our antagonists act in a competitive
manner. Platelet responses to CRP-XL were measured over a
range of concentrations in the presence or absence of 30 mM drug
(Figure 5). Losartan caused a rightward shift of the curve
compared to vehicle alone, and increased the EC50 value for
CRP-XL 3-fold (n = 4, p= 0.0008). Minima and maxima values
are equal to that of the control (Figure 5a), indicative of
competitive binding. Cinanserin also caused a rightward shift of
the curve and increased the EC50 of CRP-XL by 2-fold (n = 4,
p = 0.0487) suggesting it also acts in a competitive manner
(Figure 5b). We next measured levels of GPVI at the cell surface
by flow cytometry to experimentally verify that that the inhibitory
effects of losartan and cinanserin were not due to drug-mediated
decreases in receptor levels; neither drug affected GPVI levels
(n = 3).
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Figure 5. Losartan displays characteristics of competitive
antagonists. Platelet aggregation responses to the GPVI-specific
agonist CRP-XL were determined to a range of concentrations in the
presence or absence of 30 mM drug. Losartan (a) significantly reduced
the EC50 of CRP (F(1,58) = 15.79, p =,0.001). Cinanserin (b) also reduced
the EC50 of CRP (F(1,60) = 4.07, p = 0.048).
doi:10.1371/journal.pone.0101209.g005
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Figure 6. GPVI antagonism is unique to losartan amongst the
sartan drug class. Inhibition of collagen-induced Ca2+ release (10 mg/
ml) the sartans from fura2-AM-loaded washed human platelets was
measured and quantified (n = 3, 6 SEM).
doi:10.1371/journal.pone.0101209.g006
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GPVI antagonism by losartan is unique amongst the
sartan family
Losartan is one of a class of angiotensin receptor blockers
(ARBs) that also includes valsartan and olmesartan, amongst
others. Valsartan does not have the protective effects on
cardiovascular outcomes reported for losartan in vivo [36],
suggesting that the inhibitory effects of losartan on GPVI may
be unique amongst this drug class, and there is structural evidence
to support this [28]. Three sartans were compared with losartan
for effects on GPVI-mediated Ca2+ release to determine whether
GPVI antagonism is shared amongst this drug class. Losartan was
the most potent and efficacious inhibitor of collagen-induced Ca2+
release (10 mg/ml collagen, n = 3, Figure 6), with some activity
observed for the pro-drug olmesartan medoxomil.
Discussion
The current therapeutic strategy for managing the occurrence
of arterial thrombosis generally relies on dual antiplatelet therapy
(thienopyridines and aspirin). This approach is cost-effective and
reduces thrombotic risk, but comes at a price, with a considerable
number of patients experiencing bleeding complications. Genetic
polymorphisms can also reduce the effectiveness of both aspirin
[37–39] and the thienopyridines [40] resulting in drug ‘resistance’
in ,20–30% of patients [41].
GPVI is one of a number of potential targets that have been
proposed for the development of new antiplatelet agents [13].
Soluble GPVI-Fc fragments (Revacept) can reduce platelet
adhesion and recruitment at sites of vascular injury while having
only moderate effects on tail bleeding times in mice [42]. In
human phase I clinical trials, Revacept had no adverse effects on
health or bleeding time, with platelets showing reduced responses
to collagen, but not to ADP or thrombin, ex vivo (similar to our
observations for losartan and cinanserin in vitro). Although
Revacept may protect against pathological thrombosis, adminis-
tration requires recurrent intravenous injection and patients
cannot self-administer at home. In addition, continued adminis-
tration over prolonged periods may lead to the generation of
antibodies by the host immune system that neutralise the fusion
protein. The provision of orally available small molecule drugs
that inhibit GPVI interactions with exposed collagens may provide
a new clinical route for the long-term management of recurrent
arterial thrombosis.
To find such drugs, we adopted a drug repurposing strategy to
identify new GPVI receptor antagonists from a library of FDA-
approved drugs. Using this unbiased approach, we identified
compounds that demonstrated GPVI antagonism and selectivity
with IC50 values in the micromolar range. Losartan is a generic
FDA-approved compound for the treatment of hypertention, while
cinanserin is a 5-HT receptor antagonist which, although not used
in clinical practice for decades, has recently attracted attention as
an inhibitor of SARS coronoavirus replication [43,44]. Neither of
these compounds are associated with bleeding complications, but,
retrospectively, both had been reported to have effects on platelet
function. In addition, losartan had been shown to interact with
GPVI at the collagen binding site at/around Lys41, by NMR [28].
Due to previous observations that losartan can affect TPR
signaling [30], we looked for effects on TPR-mediated platelet
activation by the agonist U46619. Losartan inhibited TPR
signaling with an IC50 value ,10-fold higher than for GPVI. In
addition, losartan (and cinanserin) reduce FITC-fibrinogen
binding and P-selectin exposure in response to CRP-XL when
TPR is inhibited by SQ-29548. This inhibition is much greater
than that of SQ-29548 alone, demonstrating that both losartan
and cinanserin have effects on CRP-XL-induced platelet aggre-
gation not attributable to TPR. It is, therefore, reasonable to say
that based on our studies losartan is not specific for GPVI, but
displays selectivity for this receptor in washed human platelets and
whole blood experiments. Most drugs lack total specificity and hit
more than one target, and in this case, targeting both the GPVI
and the TP receptor may actually prove beneficial in terms of
antiplatelet activity. Indeed, the TP receptor antagonist terutroban
showed promise as an antiplatelet in phase II clinical trials, but was
found to offer no advantage over aspirin [5,45–47] with regards to
bleeding risk [46]. Cinanserin appears to be more selective for
GPVI than losartan, but its IC50 was high (,40 mM) and it is
unlikely to reach therapeutic levels in the blood. It may serve as a
starting point for future drug design but in terms of drug
repurposing it s not a viable candidate.
Losartan may hold more promise in terms of immediate clinical
application as an antiplatelet agent. This well-tolerated antihy-
pertensive undergoes conversion (,14%) to a metabolite
(EXP3174) that is 10–40-fold more potent than the parent drug.
Both compounds act at the ATII type I receptor to antagonise
ATII-mediated effects in vivo. A recent study demonstrated that
mice administered daily injections of losartan for 5 days exhibit
reduced platelet aggregation in response to U46619 ex vivo,
implicating losartan as a TP receptor antagonist. Mice also
demonstrate reduced thrombus formation in vivo (pathological), but
not tail bleeding times (physiological). It is interesting to note that
these in vivo outcomes are similar to that of Revacept (a soluble
GPVI-Fc fragment), which also reduces thrombus formation in vivo
while having minimal effects on physiological bleeding responses.
However, the authors of this study did not examine CRP-XL- or
collagen-induced signaling. The antagonistic effects on GPVI
signalling of losartan appears to be unique amongst the sartan
drug class – some activity is seen for the pro-drug olmesartan
medoxomil, but rapid conversion to its active form (olmesartan),
which does not antagonise GPVI-mediated Ca2+ release, is
unlikely to exert GPVI antagonism in vivo. It is likely that the
anti-platelet effects of losartan can be attributed to inhibition of
both GPVI and TP signalling. Data from the Losartan Interven-
tion For Endpoint reduction (LIFE) and follow-up studies linked
losartan with a reduction in cardiovascular mortality (stroke and
myocardial infarction) [48–50], and improved clinical outcomes.
The authors of the 2002 LIFE study state ‘losartan seems to have
benefits beyond blood pressure reduction’ [48], and it is tempting
to speculate that this could be due to its antiplatelet effects. A
similar study of valsartan (VALUE [36]) did not show any effect on
cardiovascular outcome, and this may be due to the fact that
valsartan does not have the antiplatelet properties and GPVI
antagonism that losartan does. With regards to whether losartan is
likely to reach plasma concentrations high enough to elicit
antiplatelet effects in vivo, adults given 50 mg losartan daily for
7 days have Cmax values of the parent drug, and its metabolite, of
224 ng/ml and 212 ng/ml, respectively, equating to a plasma
concentration of around 500 nM. The IC50 of losartan for CRP or
collagen induced platelet aggregation or Ca2+ release is around 2–
4 mM; a concentration of 500 nM losartan gives around 10–15%
inhibition of platelet responses to GPVI agonists in our hands.
Losartan can be given at doses of up to 150 mg per day and it is
quite possible that, certainly at higher doses, plasma levels will
reach concentrations high enough to reduce platelet responses to
collagen.
Losartan is already known to convey a 25% relative risk
reduction for stroke when compared to the non-ARB antihyper-
tensive agent, atenolol. Aspirin, although the gold standard for
antiplatelet therapy is, actually, associated with a slight increase in
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the risk of haemorrhagic stroke. Losartan is, therefore, more
efficacious than aspirin for the prevention of stroke, and not
reported to have any bleeding effects associated with its clinical
use. It is also a generic drug and therefore cost effective. Further to
this, losartan, and other ARBs and ACE inhibitors, have been
shown to improve outcomes for Alzheimer’s Disease patient by
improving cerebral blood flow and reducing inflammatory
responses [51]. It appears that losartan could offer a broad range
of health benefits in an increasingly aging population.
The work described herein supports our hypothesis that
perturbation of GPVI-collagen interactions by small molecules
can inhibit platelet aggregation, lending considerable weight to the
argument for their development as antiplatelet drugs. In summary,
we report the identification of two GPVI-selective antagonists that
may serve as a basis for future drug design (cinanserin) or
repurposing (losartan). Further work will be required to determine
the efficacy of losartan as a bone fide GPVI inhibitor in vivo, but our
study sets the scene for a new wave of antiplatelet agents that
target GPVI, and a offers a new strategy for the management of
cardiovascular risk.
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